A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Non-small Cell Lung Cancer

Trial Profile

A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Non-small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs PD-1 knockout T-cells (Primary) ; Cyclophosphamide
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Jun 2018 According to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology, secondary endpoints of this study also included 8 weeks disease control rate (DCR).
    • 05 Jun 2018 Results (n=9) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top